Recent progress in protein-protein interaction study for EGFR-targeted therapeutics
| Autor: | Rebecca C. Feiner, Kristian M. Müller |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Proteome cancer targeting Plasma protein binding virus-like particles Biochemistry 03 medical and health sciences 0302 clinical medicine ErbB1 Neoplasms antibody medicine Humans Epidermal growth factor receptor Molecular Targeted Therapy Protein Interaction Maps EGF-R Molecular Biology Protein Kinase Inhibitors Tumor marker antigen-binding scaffolds biology tumor targeting Cancer Protein engineering medicine.disease ErbB Receptors 030104 developmental biology 030220 oncology & carcinogenesis Immunology Cancer research biology.protein Signal transduction Tyrosine kinase Protein Binding Signal Transduction |
| DOI: | 10.1080/14789450.2016.1212665 |
| Popis: | Introduction: Epidermal growth factor receptor (EGFR) expression is upregulated in many tumors and its aberrant signaling drives progression of many cancer types. Consequently, EGFR has become a clinically validated target as extracellular tumor marker for antibodies as well as for tyrosine kinase inhibitors. Within the last years, new mechanistic insights were uncovered and, based on clinical experience as well as progress in protein engineering, novel bio-therapeutic approaches were developed and tested.Areas covered: The potential therapeutic targeting arsenal in the fight against cancer now encompasses bispecific or biparatopic antibodies, DARPins, Adnectins, Affibodies, peptides and combinations of these binding molecules with viral- and nano-particles. We review past and recent binding proteins from the literature and include a brief description of the various targeting approaches. Special attention is given to the binding modes with the EGFR.Expert commentary: Clinical data from the three approved anti EGFR antibodies indicate that there is room for improved therapeutic efficacy. Having choices in size, affinity, avidity and the mode of EGFR binding as well as the possibility to combine various effector functions opens the possibility to rationally design more effective therapeutics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|